Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19

被引：92

作者：

Tang, Lingling ^{[1
]}

Jiang, Yingan ^{[2
]}

Zhu, Mengfei ^{[1
]}

Chen, Lijun ^{[3
]}

Zhou, Xiaoyang ^{[2
]}

Zhou, Chenliang ^{[2
]}

Ye, Peng ^{[2
]}

Chen, Xiaobei ^{[2
]}

Wang, Baohong ^{[3
]}

Xu, Zhenyu ^{[4
]}

Zhang, Qiang ^{[4
]}

Xu, Xiaowei ^{[3
]}

Gao, Hainv ^{[1
]}

Wu, Xiaojun ^{[2
]}

Li, Dong ^{[2
]}

Jiang, Wanli ^{[2
]}

Qu, Jingjing ^{[3
]}

Xiang, Charlie ^{[3
]}

Li, Lanjuan ^{[1
,3
]}

机构：

[1] Zhejiang Shuren Univ, Shulan Int Med Coll, Shulan Hangzhou Hosp, Hangzhou 310022, Peoples R China

[2] Wuhan Univ, Dept Infect Dis, Renmin Hosp, Wuhan 430060, Peoples R China

[3] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Affiliated Hosp 1,Coll Med,Natl Clin Res Ctr Infe, Hangzhou 310003, Peoples R China

[4] Innovat Precis Med IPM Grp, Hangzhou 311215, Peoples R China

来源：

FRONTIERS OF MEDICINE | 2020年 / 14卷 / 05期

基金：

国家重点研发计划;

关键词：

Coronavirus disease 2019 (COVID-19); mesenchymal stem cell; acute respiratory distress syndrome; stem cell therapeutics; SPIKE PROTEIN; DIFFERENTIATION; TRANSPLANTATION; INHIBITION; INFECTION; IMPROVES; THERAPY;

D O I：

10.1007/s11684-020-0810-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was identified in December 2019. The symptoms include fever, cough, dyspnea, early symptom of sputum, and acute respiratory distress syndrome (ARDS). Mesenchymal stem cell (MSC) therapy is the immediate treatment used for patients with severe cases of COVID-19. Herein, we describe two confirmed cases of COVID-19 in Wuhan to explore the role of MSC in the treatment of COVID-19. MSC transplantation increases the immune indicators (including CD4 and lymphocytes) and decreases the inflammation indicators (interleukin-6 and C-reactive protein). High-flow nasal cannula can be used as an initial support strategy for patients with ARDS. With MSC transplantation, the fraction of inspired O-2(FiO(2)) of the two patients gradually decreased while the oxygen saturation (SaO(2)) and partial pressure of oxygen (PO2) improved. Additionally, the patients' chest computed tomography showed that bilateral lung exudate lesions were adsorbed after MSC infusion. Results indicated that MSC transplantation provides clinical data on the treatment of COVID-19 and may serve as an alternative method for treating COVID-19, particularly in patients with ARDS.

引用

页码：664 / 673

页数：10

共 51 条

[21]

[Anonymous], 2016, LANCET HAEMATOL, DOI DOI 10.1016/S2352-3026(15)00224-0

[22]

[Anonymous], 2018, INT J RAD ONCOL BIOL, DOI DOI 10.1016/J.IJROBP.2018.04.007

[23]

[Anonymous], 2014, STEM CELLS DEV, DOI DOI 10.1089/SCD.2013.0390

[24]

[Anonymous], 2015, LANCET RESP MED, DOI DOI 10.1016/S2213-2600(14)70291-7

[25]

[Anonymous], 2020, LANCET, DOI DOI 10.1016/S0140-6736(20)30185-9

[26]

[Anonymous], 2018, BIOPRESERV BIOBANK, DOI DOI 10.1089/BIO.2017.0057

[27]

[Anonymous], 2019, STEM CELL RES THER, DOI DOI 10.1186/S13287-019-1156-6

[28]

[Anonymous], 2020, J MED VIROL, DOI DOI 10.1002/JMV.25733

[29]

[Anonymous], LANCET

[30]

[Anonymous], 2005, CLIN IMMUNOL, DOI DOI 10.1016/J.CLIM.2005.08.004

← 1 2 3 4 5 6 →